Glycerin
As of the edition of 20 October 2026, Glycerin is a small molecule: marketed, first approved in 1936 (ES).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Procalamine
- First approved
- 1 April 1936 (ES)
- Approvals on record
- 10 in 5 regions
- Holder of the most recent approval
- AbbVie; 8 holders in all
- Registered trials
- 29, 5 stopped early
- Disease areas
- Eye; Nutrition and metabolism; Hormones; Skin and connective tissue; Bones, joints and muscles; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 16 | 9 | 1 | 2 |
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 1 | 0 | 0 | 1 |
| Phase 3 | 3 | 3 | 0 | 0 |
| Phase 4 | 8 | 4 | 2 | 1 |
| All trials | 29 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Alk-Abello | Applicant | 1963 to now |
| Alcon | Later holder | 2003 to now |
| Bausch Health | Later holder | 2004 to now |
| AbbVie | Later holder and Lead sponsor of trials | 2005 to now |